Image of the month

York, Gary L.; Meadows, John G.

doi:10.1053/j.gastro.2005.01.019

Cited by 5 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastrointestinal tract involvement occurs in around 60% of metastatic melanoma patients with only 4% diagnosed before death 1. Initial presentation with duodenal metastasis is unusual and limited to case reports,2 with typical symptoms including abdominal pain, bleeding and obstruction due to intussusception. Lesions are typically polypoidal and may be multiple 3…”

Section: Discussionmentioning

confidence: 99%

Editor's snapshot: an unexpected duodenal finding

Nelson

Bain

Graham

et al. 2012

Gut

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Editor's snapshot: an unexpected duodenal finding

Nelson

Bain

Graham

et al. 2012

Gut

View full text Add to dashboard Cite

“…Furthermore, melanoma often exhibits distant metastasis during the advanced stages of its progression 10 . Among them, brain metastasis and lung metastasis are among the most common pathways of melanoma metastasis 11 . Studies have shown that up to 60% of melanoma patients develop brain metastasis during the course of disease progression 12 .…”

Section: Introductionmentioning

confidence: 99%

Fluoxetine as a Potential Therapeutic Agent for Inhibiting Melanoma Brain and Lung Metastasis: Induction of Apoptosis, G0/G1 Cell Cycle Arrest, and Disruption of Autophagy Flux

He,

Wu,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Brain metastases and lung metastases are major causes of treatment failure and related mortality in melanoma. Fluoxetine hydrochloride (FXT), a widely-used antidepressant, has emerged as a potential anticancer agent in preclinical studies. Previous research has shown its potential to inhibit melanoma. However, its efficacy and the underlying mechanisms in melanoma metastasis, especially concerning brain metastases and lung metastases, remain underexplored. This study investigates FXT's inhibitory effects on melanoma growth and metastasis to the lung and brain. Employing a combination of in vitro assays, we demonstrate FXT's potent suppression of melanoma growth through induction of intrinsic apoptosis, disruption of autophagic flux, and cell cycle arrest at the G0/G1 phase. In in vivo mouse models, we found that FXT exhibits strong inhibitory activity against melanoma brain metastases and lung metastases. Our findings provide a foundation for future clinical exploration of FXT as a novel treatment strategy for melanoma, underscoring its ability to target both primary and metastatic lesions.

show abstract

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update

2014

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are used extensively for the treatment of gastric acid-related disorders, often over the long term, which raises the potential for clinically significant drug interactions in patients receiving concomitant medications. These drug–drug interactions have been previously reviewed. However, the current knowledge is likely to have advanced, so a thorough review of the literature published since 2006 was conducted. This identified new studies of drug interactions that are modulated by gastric pH. These studies showed the effect of a PPI-induced increase in intragastric pH on mycophenolate mofetil pharmacokinetics, which were characterised by a decrease in the maximum exposure and availability of mycophenolic acid, at least at early time points. Post-2006 data were also available outlining the altered pharmacokinetics of protease inhibitors with concomitant PPI exposure. New data for the more recently marketed dexlansoprazole suggest it has no impact on the pharmacokinetics of diazepam, phenytoin, theophylline and warfarin. The CYP2C19-mediated interaction that seems to exist between clopidogrel and omeprazole or esomeprazole has been shown to be clinically important in research published since the 2006 review; this effect is not seen as a class effect of PPIs. Finally, data suggest that coadministration of PPIs with methotrexate may affect methotrexate pharmacokinetics, although the mechanism of interaction is not well understood. As was shown in the previous review, individual PPIs differ in their propensities to interact with other drugs and the extent to which their interaction profiles have been defined. The interaction profiles of omeprazole and pantoprazole sodium (pantoprazole-Na) have been studied most extensively. Several studies have shown that omeprazole carries a considerable potential for drug interactions because of its high affinity for CYP2C19 and moderate affinity for CYP3A4. In contrast, pantoprazole-Na appears to have lower potential for interactions with other medications. Lansoprazole and rabeprazole also seem to have a weaker potential for interactions than omeprazole, although their interaction profiles, along with those of esomeprazole and dexlansoprazole, have been less extensively investigated. Only a few drug interactions involving PPIs are of clinical significance. Nonetheless, the potential for drug interactions should be considered when choosing a PPI to manage gastric acid-related disorders. This is particularly relevant for elderly patients taking multiple medications, or for those receiving a concomitant medication with a narrow therapeutic index.

show abstract

Image of the month

Cited by 5 publications

References 1 publication

Editor's snapshot: an unexpected duodenal finding

Editor's snapshot: an unexpected duodenal finding

Fluoxetine as a Potential Therapeutic Agent for Inhibiting Melanoma Brain and Lung Metastasis: Induction of Apoptosis, G0/G1 Cell Cycle Arrest, and Disruption of Autophagy Flux

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update

Contact Info

Product

Resources

About